Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA
LK Billings,1,2 M Mocarski,3 A Basse,4 B Hunt,5 WJ Valentine,5 E Jodar6 1Division of Endocrinology and Metabolism, NorthShore University HealthSystem, Skokie, IL, USA; 2Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL, USA; 3Value Evidence and Outcomes, Novo Nor...
Saved in:
Main Authors: | Billings LK (Author), Mocarski M (Author), Basse A (Author), Hunt B (Author), Valentine WJ (Author), Jodar E (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2019-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system
by: Psota M, et al.
Published: (2017) -
Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy
by: Pöhlmann J, et al.
Published: (2019) -
Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration
by: Samantha Walczuk, et al.
Published: (2024) -
Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2
by: I. N. Dyakov, et al.
Published: (2020) -
Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
by: Sondra Davis, et al.
Published: (2017)